JAGX
Jaguar Health, Inc.
Key Financials
Operating Income
$-45908000
↓ 48.9%
Revenue
$11.5M
↓ 1.5%
Net Income
$-53575000
↓ 39.2%
Total Assets
$38.3M
↓ 28.3%
EPS (Diluted)
$-22.97
↑ 82.4%
Total Liabilities
$57.0M
↑ 28.3%
Shareholders' Equity
$17.2M
↑ 61.2%
Cash & Equivalents
$968000.00
↓ 87.9%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| NT 10-Q | 8/14/2026 | View on SEC |
| POS AM | 8/11/2026 | View on SEC |
| DEF 14A | 8/3/2026 | View on SEC |
| 424B3 | 7/27/2026 | View on SEC |
| 424B3 | 7/27/2026 | View on SEC |
| EFFECT | 7/24/2026 | View on SEC |
| EFFECT | 7/24/2026 | View on SEC |
| PRE 14A | 7/24/2026 | View on SEC |
| S-1/A | 7/24/2026 | View on SEC |
| S-1 | 7/16/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | JAGX |
| Company Name | Jaguar Health, Inc. |
| CIK | 1585608 |
| Sector | Pharmaceutical Preparations |
| Industry | Non-accelerated filer Smaller reporting company |
| Exchange | Nasdaq |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | 415-371-8300 |